Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Company Highlights CD228V as its Principal Development Priority, Proposed SPAC Business Combination at ~ $135 Million Valuation for SkinJect® and Teverelix® as a Partner-Ready Program PHILADELPHIA, PA / ACCESS Newswire / November 6, 2026 / …